Monoamine releasing agent

Types and selectivity

MRAs can be classified by the monoamines they mainly release, although these drugs lie on a spectrum:

• Selective for one neurotransmitter
  • Norepinephrine releasing agent (NRA) (e.g., ephedrine, levomethamphetamine)
  • Dopamine releasing agent (DRA) (no robustly selective agents known)
  • Serotonin releasing agent (SRA) (e.g., chlorphentermine, MMAI)
• Non-selective, releasing two or more neurotransmitters
  • Norepinephrine–dopamine releasing agent (NDRA) (e.g., amphetamine, methamphetamine)
  • Serotonin–norepinephrine releasing agent (SNRA) (e.g., fenfluramine, MDAI)
  • Serotonin–dopamine releasing agent (SDRA) (e.g., 5-chloro-αMT, BK-NM-AMT)
  • Serotonin–norepinephrine–dopamine releasing agent (SNDRA) (e.g., MDMA, mephedrone)

The differences in selectivity of MRAs is the result of different affinities as substrates for the monoamine transporters, and thus differing ability to gain access into monoaminergic neurons and induce monoamine neurotransmitter release.

As of present, no selective DRAs are known. This is because it has proven extremely difficult to separate DAT affinity from NET affinity and retain releasing efficacy at the same time. Several selective SDRAs, including tryptamine, (+)-α-ethyltryptamine (αET), 5-chloro-αMT, and 5-fluoro-αET, are known. However, besides their serotonin release, many of these compounds additionally act as non-selective serotonin receptor agonists, including of the serotonin 5-HT2A receptor (with accompanying hallucinogenic effects), and some of them are known to act as monoamine oxidase inhibitors.

Effects and uses

MRAs can produce varying effects depending on their selectivity for inducing the release of different monoamine neurotransmitters.

Selective SRAs such as chlorphentermine have been described as dysphoric and lethargic. Less selective SRAs that also stimulate the release of dopamine, such as methylenedioxymethamphetamine (MDMA), are described as more pleasant, more reliably elevating mood and increasing energy and sociability. SRAs have been used as appetite suppressants and as entactogens. They have also been proposed for use as more effective antidepressants and anxiolytics than selective serotonin reuptake inhibitors (SSRIs) because they can produce much larger increases in serotonin levels in comparison.

DRAs, usually non-selective for both norepinephrine and dopamine, have psychostimulant effects, causing an increase in energy, motivation, elevated mood, and euphoria. Other variables can significantly affect the subjective effects, such as infusion rate (increasing positive effects of DRAs) and psychological expectancy effects. They are used in the treatment of attention deficit hyperactivity disorder (ADHD), as appetite suppressants, wakefulness-promoting agents, to improve motivation, and are drugs of recreational use and misuse.

Selective NRAs are minimally psychoactive, but as demonstrated by ephedrine, may be distinguished from placebo, and may trends towards liking. They may also be performance-enhancing, in contrast to reboxetine which is solely a norepinephrine reuptake inhibitor. In addition to their central effects, NRAs produce peripheral sympathomimetic effects like increased heart rate, blood pressure, and force of heart contractions. They are used as nasal decongestants and bronchodilators, but have also seen use as wakefulness-promoting agents, appetite suppressants, and antihypotensive agents. They have additionally seen use as performance-enhancing drugs, for instance in sports.

Mechanism of action

Mechanisms of monoamine release by MRAs

MRAs induce the release of the monoamine neurotransmitters serotonin, norepinephrine, and/or dopamine from monoaminergic neurons in the brain and/or periphery. MRAs are substrates of the plasma membrane-associated monoamine transporters (MATs), including of the serotonin transporter (SERT), norepinephrine transporter (NET), and/or dopamine transporter (DAT), and enter presynaptic monoaminergic neurons via these transporters. To a much lesser extent, sufficiently lipophilic MRAs may also passively diffuse into monoaminergic neurons. Once in the intracellular space of the neuron, MRAs reverse the direction of the MATs, as well as of the organic cation transporter 3 (OCT3), such that they mediate efflux of cytosolic monoamine neurotransmitters into the extracellular synaptic cleft rather than the usual reuptake. Many, though notably not all MRAs, additionally act at the vesicular monoamine transporter 2 (VMAT2) on synaptic vesicles to enhance the pool of cytosolic monoamine neurotransmitters available for efflux. However, MRAs can still induce monoamine release without VMAT2, for instance by releasing newly synthesized cytosolic neurotransmitters. In addition to their induction of monoamine release, MRAs act less potently as monoamine reuptake inhibitors (MRIs). This is due to substrate competition with monoamine neurotransmitters for the MATs and/or induction of MAT internalization and consequent inactivation. The monoamine neurotransmitters released by MRAs bind to and activate monoamine receptors on presynaptic and postsynaptic neurons to facilitate monoaminergic neurotransmission. As such, MRAs can be described as indirect monoamine receptor agonists.

The mechanisms by which MRAs induce MAT reverse transport and efflux are complex and incompletely understood. The process appears to depend on a number of intracellular changes, including sodium ion (Na+) and calcium ion (Ca2+) elevation, protein kinase C (PKC) activation, and Ca2+/calmodulin-dependent protein kinase II alpha (CaMKIIα) activation, among others. Activation of protein kinases including PKC, CaMKIIα, and others results in phosphorylation of the MATs causing them to mediate efflux instead of reuptake. Exactly how MRAs induce the preceding effects is unclear however. A more recent study suggests that intracellular Ca2+ elevation, PKC activation, and CaMKIIα might all be dispensable for MRA-induced monoamine release, but more research is needed.

The trace amine-associated receptor 1 (TAAR1) is a receptor for trace amines like β-phenethylamine and tryptamine, as well as for monoamine neurotransmitters like dopamine and serotonin, and is a known target of many MRAs, such as amphetamine and methamphetamine. The TAAR1 is a largely intracellular receptor expressed both in presynaptic and postsynaptic monoaminergic neurons and appears to be extensively co-localized with MATs in the brain. Some in-vitro studies have found that TAAR1 agonism by MAT substrates like MRAs can produce PKC activation and thereby induce MAT reverse transport and monoamine efflux. As such, TAAR1 agonism, coupled with MAT substrate activity, could mediate or contribute to the monoamine release of MRAs. However, findings in this area are conflicting, with other studies unable to replicate the results. In addition, MRAs can still induce monoamine efflux in the absence of TAAR1 in vitro, well-known MRAs like amphetamine and methamphetamine exhibit only low-potency human TAAR1 agonism that is of uncertain general significance in humans, many other MRAs are inactive as TAAR1 agonists in humans, the monoamine release and behavioral effects of amphetamines are not only preserved but substantially augmented in TAAR1 knockout mice, and the monoamine release and behavioral effects of amphetamines are strongly reduced or abolished in mice with TAAR1 overexpression. Besides induction of monoamine release, TAAR1 agonism, as well as other mechanisms, may mediate MAT internalization. MAT internalization may limit the capacity of MRAs to induce MAT reverse transport and monoamine efflux. TAAR1 signaling also activates G protein-coupled inwardly rectifying potassium channels (GIRKs) and thereby robustly inhibits the firing rates of brain monoaminergic neurons and suppresses exocytotic monoamine release. Due to the preceding mechanisms, potent TAAR1 agonism by MRAs that possess this action may actually auto-inhibit and constrain their monoaminergic effects.

Although induction of MAT reverse transport and consequent monoamine efflux is the leading theory of how MRAs act, an alternative and more recent theory has proposed that amphetamine, at therapeutic doses, may not actually act by inducing DAT reverse transport and dopamine efflux, but instead by augmenting exocytotic dopamine release and hence by enhancing phasic rather than tonic dopaminergic signaling. According to this model, DAT reverse transport may only be relevant at supratherapeutic doses and may be more associated with toxicity, for instance induction of psychosis. It is unclear how amphetamine might act to enhance exocytotic dopamine release, and more research is needed to evaluate this theory.

Aside from the mechanisms mediating the monoamine release of MRAs, other targets of some MRAs, such as the intracellular sigma σ1 receptor, have been found to inhibit MRA-induced monoamine efflux via interactions with the MATs. Conversely, activation of the sigma σ2 receptor has been found to potentiate amphetamine-induced dopamine efflux. The mechanism mediating this effect is unknown, but it has been postulated that it may be due to elevation of intracellular calcium and consequent downstream effects.

Differences from physiological release and reuptake inhibitors

The neurotransmitter release induced by MRAs is very different from normal exocytotic monoamine release, in which action potentials trigger synaptic vesicles to fuse with the cell membrane and release neurotransmitters into the synaptic cleft. In relation to this, MRAs promote tonic monoaminergic signaling, whereas normal exocytotic monoamine release involves phasic monoaminergic signaling.

The enhancement of monoaminergic signaling by MRAs also differs from that with MRIs. Because MRIs block monoamine neurotransmitter reuptake and consequent inactivation following action potentials and exocytotic release, they preferentially augment phasic monoaminergic signaling rather than tonic signaling. In addition, inhibitory presynaptic and somatodendritic monoamine autoreceptors, including serotonin 5-HT1A and 5-HT1B autoreceptors, dopamine D2 and D3 autoreceptors, and α2-adrenergic autoreceptors, respond to elevated synaptic monoamine neurotransmitter levels by inhibiting presynaptic monoaminergic neuron firing rates, and this substantially limits the effects of MRIs. In contrast, MRAs do not depend on action potentials to induce monoamine release, and thus are able to largely bypass the negative feedback mediated by autoreceptors. Relatedly, MRAs can induce far greater maximal increases in monoamine neurotransmitter levels than MRIs. For instance, MRIs can achieve maximal elevations in brain monoamine levels of about 5- to 10-fold in animals, whereas MRAs can produce elevations of as much as 10- to 50-fold, with no clear ceiling limit. Since MRAs depend on uptake by the MATs to induce monoamine release, their mediation of monoamine release and consequent effects can be blocked by MRIs.

Structural requirements and partial MRAs

There is a constrained and relatively small molecular size requirement for compounds to act as MRAs. This is because they must be small enough to serve as substrates of the monoamine transporters and thereby be transported inside of monoaminergic neurons by these proteins, in turn allowing them to induce monoamine neurotransmitter release. Compounds with chemical features extending beyond the size constraints for releasers will instead act as partial releasers, reuptake inhibitors, or be inactive. Partial releasers show reduced maximal efficacy in releasing monoamine neurotransmitters compared to conventional full releasers. While most MRAs are full releasers, a number of partial releasers are known and may have atypical properties. Examples of partial releasers include 3,4-methylenedioxyethylamphetamine (MDEA), N-ethylnaphthylaminopropane (ENAP), 3-trifluoromethyl-4-chlorophenylpiperazine (TFMCPP), para-nitrophenylpiperazine (pNPP), bretisilocin, and psilocin. The mechanisms responsible for the differences between full releasers and partial releasers are largely unknown.

Other related agents

DAT "inverse agonists"

Dopamine reuptake inhibitors (DRIs) have been grouped into two types, typical or conventional DRIs like cocaine, WIN-35428 (β-CFT), and methylphenidate that produce potent psychostimulant, euphoric, and reinforcing effects, and atypical DRIs like vanoxerine (GBR-12909), modafinil, benztropine, and bupropion, which do not produce such effects or have greatly reduced such effects. It has been proposed that typical DRIs may not actually be acting primarily as DRIs but rather as dopamine releasing agents (DRAs) via mechanisms distinct from conventional substrate-type DRAs like amphetamines. A variety of different pieces of evidence support this hypothesis and help to explain otherwise confusing findings. For example, typical DRIs like cocaine and methylphenidate can robustly increase brain dopamine levels similarly to substrate-type DRAs like amphetamine, whereas atypical DRIs, which are viewed as simple competitive reuptake inhibitors, achieve much more modest increases. Under this model, typical cocaine-like DRIs have been referred to with the new label of dopamine transporter (DAT) "inverse agonists" to distinguish them from conventional substrate-type DRAs. An alternative theory is that typical DRIs and atypical DRIs stabilize the DAT in different conformations, with typical DRIs resulting in an outward-facing open conformation that produces differing pharmacological effects from those of atypical DRIs.

Monoaminergic activity enhancers

Some MRAs, like the amphetamines amphetamine and methamphetamine, as well as trace amines like phenethylamine, tryptamine, and tyramine, are additionally monoaminergic activity enhancers (MAEs). That is, they enhance the action potential-mediated release of monoamine neurotransmitters (in contrast to MRAs, which induce uncontrolled monoamine release independent of neuronal firing). They are usually active as MAEs at much lower concentrations than those at which they induce monoamine release. The MAE actions of MAEs may be mediated by TAAR1 agonism, which has likewise been implicated in monoamine-releasing actions in some studies. MAEs without concomitant potent monoamine-releasing actions, like selegiline (L-deprenyl), phenylpropylaminopentane (PPAP), and benzofuranylpropylaminopentane (BPAP), have been developed.

Endogenous MRAs

A number of endogenous compounds are known to act as MRAs. These include the monoamine neurotransmitters dopamine (an DRA), norepinephrine (an NRA), and serotonin (an SRA) themselves, as well as the trace amines phenethylamine (an NDRA), tryptamine (an SDRA or imbalanced SNDRA), and tyramine (an NDRA). Synthetic MRAs are substantially based on structural modification of these endogenous compounds, most prominently including the substituted phenethylamines and substituted tryptamines.

Release of monoamine neurotransmitters by themselves, for instance in the cases of serotonin, norepinephrine, and dopamine, has been referred to as "self-release". The physiological significance of the findings that monoamine neurotransmitters can act as releasing agents of themselves is unclear. However, it could imply that efflux is a common neurotransmitter regulatory mechanism that can be induced by any transporter substrate.

It is possible that monoamine neurotransmitter self-release could be a protective mechanism. It is notable in this regard that intracellular non-vesicular or cytoplasmic dopamine is toxic to neurons and that the vesicular monoamine transporter 2 (VMAT2) is neuroprotective by packaging this dopamine into synaptic vesicles. Along similar lines, MRAs induce the efflux of non-vesicular monoamine neurotransmitter and thereby move cytoplasmic neurotransmitter into the extracellular space. On the other hand, many MRAs but not all also act as VMAT2 inhibitors and reversers, and hence concomitantly induce the release of vesicular monoamine neurotransmitters like dopamine into the cytoplasm. Induction of VMAT2 efflux by MRAs appears to be related to their monoaminergic neurotoxicity.

Monoaminergic neurotoxicity

Main article: Monoaminergic neurotoxin

Some MRAs have been found to act as monoaminergic neurotoxins and hence to produce long-lasting damage to monoaminergic neurons. Examples include dopaminergic neurotoxicity with amphetamine and methamphetamine and serotonergic neurotoxicity with methylenedioxymethamphetamine (MDMA). Amphetamine may produce significant dopaminergic neurotoxicity even at therapeutic doses. However, clinical doses of amphetamine producing neurotoxicity is controversial and disputed. In contrast to amphetamines, monoamine reuptake inhibitors like methylphenidate lack apparent neurotoxic effects.

Analogues of MDMA with retained MRA activity but reduced or no serotonergic neurotoxicity, like 5,6-methylenedioxy-2-aminoindane (MDAI) and 5-iodo-2-aminoindane (5-IAI), have been developed. Certain drugs have been found to block the neurotoxicity of MRAs in animals. For instance, the selective MAO-B inhibitor selegiline has been found to prevent the serotonergic neurotoxicity of MDMA in rodents.

Chemical families

MRAs are usually arylalkylamines. A number of different structural families of compounds have been found to act as MRAs. The possible structural forms of MRAs are limited by a small molecular size requirement for activity. Molecules that are too large become monoamine reuptake inhibitors as they can no longer be transported into neurons by the monoamine transporters and induce monoamine release intracellularly.

Phenethylamine-like

• Phenethylamines (2-phenylethylamines) (e.g., phenethylamine, tyramine, dopamine, norepinephrine)
  • Amphetamines (α-methylphenethylamines) (e.g., amphetamine, methamphetamine, fenfluramine)
    • Cathinols (β-hydroxyamphetamines) (e.g., phenylpropanolamine, ephedrine, pseudoephedrine, cathine)
    • Cathinones (β-ketoamphetamines) (e.g., cathinone, methcathinone, mephedrone)
    • Phentermines (α-methylamphetamines) (e.g., phentermine, mephentermine, chlorphentermine, clortermine)
    • Phenylisobutylamines (α-ethylphenethylamines) (e.g., phenylisobutylamine, , , buphedrone)
    • Ring-extended amphetamines
      • Benzodioxolylaminopropanes (methylenedioxyamphetamines) (e.g., , , , methylone)
        • Methylenedioxycathinones (e.g., methylone, ethylone, butylone)
        • Methylenedioxyphentermines (e.g., , )
        • Benzodioxolylisobutylamines (e.g., , , butylone)
      • Benzodioxanylaminopropanes (ethylenedioxyamphetamines) (e.g., , , )
      • Benzofuranylaminopropanes (e.g., 4-APB, 5-APB, 5-MAPB, 6-APB, 6-MAPB, 5-APDB, 5-MAPDB, 6-APDB, 6-MAPDB, 7-APB, IBF5MAP)
        • Benzofuranylisobutylamines (e.g., 5-MBPB, 6-MBPB)
      • Benzothiophenylaminopropanes (e.g., 4-APBT, 5-APBT, 5-MAPBT, 6-APBT, 7-APBT)
      • Indolylaminopropanes (e.g., 5-IT/5-API, 6-IT/6-API)
      • Indanylaminopropanes (e.g., 5-APDI/IAP, 5-MAPDI)
      • Naphthylaminopropanes (e.g., , methamnetamine/MNAP, , BMAPN)
      • Tetralinylaminopropanes (e.g., 6-APT/TAP)
      • Other ring-extended amphetamines (e.g., ODMA, SeDMA, TDMA)
• Cyclopentylaminopropanes (e.g., isocyclamine, cyclopentamine)
• Cyclohexylaminopropanes (e.g., norpropylhexedrine, propylhexedrine)
• Phenylpropylamines (e.g., phenylpropylamine, homo-MDA, homo-MDMA)
• Thiophenylisopropylamines (e.g., thiopropamine, methiopropamine, thiothinone)
• Phenylalkenylamines and phenylalkynylamines (e.g., phenylbutynamine, phenylbutenamine)
• Other possible groups (e.g., 2-furylethylamines, 2-tetrahydrofurylethylamines, 2-pyrrolylethylamines, 3-pyrrolylethylamines)

Amine fused into ring

• Phenylalkylpyrrolidines (e.g., , )
  • Methylenedioxyphenylalkylpyrrolidines (e.g., )
• Phenylmorpholines (e.g., phenmetrazine, phendimetrazine)
  • Methylenedioxyphenylmorpholines (e.g., )
  • Naphthylmorpholines (e.g., naphthylmorpholine, naphthylmetrazine)
• Phenyloxazolamines (e.g., aminorex, 4-methylaminorex, pemoline)
• Benzylpiperazines (e.g., 1-benzylpiperazine, )
  • Methylenedioxybenzylpiperazines (e.g., , fipexide)
• Benzylpiperidines (e.g., 4-benzylpiperidine)
• Phenylpiperazines (e.g., 1-phenylpiperazine, , , , , )

Alkyl chain fused into ring

• 2-Aminoindanes (e.g., 2-aminoindane (2-AI), , , , , , )
  • Methylenedioxyaminoindanes (e.g., , )
  • Benzofurancyclopentanylamines (e.g., )
• 2-Aminotetralins (e.g., 2-aminotetralin, )
  • Methylenedioxyaminotetralins (e.g., , )
• Other possible groups (e.g., benzylamines (e.g., MDM1EA), 2-amino-1,2-dihydronaphthalenes (e.g., ), aminobenzocycloheptenes (e.g., , ))

Tryptamine-like

• Tryptamines (2-(3-indolyl)ethylamines) (e.g., tryptamine, serotonin, bufotenin, , psilocin, bretisilocin)
  • α-Alkyltryptamines (e.g., (3-API), , 5-chloro-αMT, 5-fluoro-αMT)
    • β-Keto-α-alkyltryptamines (e.g., BK-NM-AMT, BK-5F-NM-AMT, BK-5Cl-NM-AMT, BK-5Br-NM-AMT)
• Isotryptamines (2-(1-indolyl)ethylamines) (e.g., isoAMT)
• Indolizinylaminopropanes (e.g., 1ZP2MA, 1Z2MAP1O)
• Benzothiophenylaminopropanes (e.g., 2-APBT, 3-APBT)
• Benzofuranylaminopropanes (e.g., 2-APB, 2-MAPB, 3-APB)
• Other possible groups (e.g., 2-pyrrolylethylamines, 3-pyrrolylethylamines)

Ring-less (alkylamines)

• Alkylamines (e.g., , , heptaminol, iproheptine, isometheptene, methylhexanamine/1,3-DMAA, octodrine, oenethyl, tuaminoheptane)

Chemical family structures gallery

| File:Phenethylamine2DCSD.svg | Phenethylamine | File:Amphetamine.svg | Amphetamine | File:Phenylpropanolamine.svg | Phenylpropanolamine | File:Cathinone.svg | Cathinone | File:Fentermina.svg | Phentermine | File:Alpha-Ethylphenethylamine.png | Phenylisobutylamine | File:MDA-2D-skeletal.svg | | File:BDB.svg | | File:Ethylenedioxymethamphetamine.svg | | File:5-APB2DACS.svg | 5-APB | File:6APB.svg | 6-APB | File:3-desoxy-MDA.svg | 5-APDB | File:4-desoxy-MDA.svg | 6-APDB | File:IBF5MAP structure.png | IBF5MAP | File:5-MBPB structure.png | 5-MBPB | File:5-MAPBT.svg | 5-MAPBT | File:5-IT Structure.svg | 5-IT/5-API | File:6-API.svg | 6-IT/6-API | File:Indanylaminopropane.svg | 5-APDI/IAP | File:Naphthylisopropylamine.svg | Naphthylaminopropane | File:Tetralinylaminopropane.svg | 6-APT/TAP | File:ODMA.svg | ODMA | File:SeDMA.svg | SeDMA | File:TDMA structure.svg | TDMA | File:Cyclopentamine.svg | Cyclopentamine | File:Propylhexedrine.svg | Propylhexedrine | File:Thiopropamine.svg | Thiopropamine | File:A-PPP.svg | | File:Phenmetrazine.svg | Phenmetrazine | File:Aminorex structure.svg | Aminorex | File:Benzylpiperazine.svg | 1-Benzylpiperazine | File:4-Benzylpiperidine Structure.svg | 4-Benzylpiperidine | File:N-phenylpiperazine.svg | 1-Phenylpiperazine | File:2-Aminoindane.svg | 2-Aminoindane | File:MDAI.svg | MDAI | File:2-Aminotetralin Structure.svg | 2-Aminotetralin | File:6,7-Methylenedioxy-2-aminotetralin.svg | MDAT | File:2-Aminodilin.png | 2-Amino-1,2-dihydronaphthalene | File:Tryptamine.svg | Tryptamine | File:AMT.svg | α-Methyltryptamine | File:AET.svg | α-Ethyltryptamine | File:Β-Keto-N-methyl-αMT.svg | BK-NM-AMT | File:Alpha-Methylisotryptamine.svg | isoAMT | File:2MAPB structure.png | 2-MAPB | File:Dimethylbutylamine.svg | 1,3-Dimethylbutylamine | File:Heptaminol.svg | Heptaminol | File:Iproheptine.png | Iproheptine | File:Isometheptene.svg | Isometheptene | File:Geranamine.svg | Methylhexanamine | File:Octodrine.png | Octodrine | File:Oenethyl.svg | Oenethyl | File:Tuaminoheptane.png | Tuaminoheptane

Activity profiles

The activities of many MRAs in terms of their potencies, efficacies, and selectivities for monoamine release induction in vitro have been characterized in numerous studies in the scientific literature. These studies have been especially conducted by the research lab led by Richard B. Rothman and Michael H. Baumann at the National Institute on Drug Abuse (NIDA). These researchers developed an assay measuring monoamine release from rat brain synaptosomes in 1999 that has subsequently been widely employed. The data with this procedure from many relevant studies are provided in the table below. The Rothman and Baumann lab refers to these data as the "Phenyl Amine Library", "Phenethylamine Library", "Phenylethylamine Library", or "PAL" library, a large library of values of phenethylamine analogs at the monoamine transporters (1,400compounds as of 2015), and has designated PAL-# code names for the drugs included in it.

Another method of measuring monoamine release involves the use of human HEK293 cells transfected with and expressing monoamine transporters. However, MRAs show differing and much lower potencies in this system compared to rat brain synaptosomes, and it is much less frequently employed. The reasons for these differences are not entirely clear, but may be related to species differences, differences in release assay methods, and/or absence of important neuronal membrane proteins in non-neuronal HEK293 cells.

In addition to the potencies of MRAs in terms of their MRA activity, data on the affinities (Ki) of various MRAs for the monoamine transporters (MATs) and their potencies () in acting as monoamine reuptake inhibitors (MRIs) have been published. Activities of MRAs at the vesicular monoamine transporter 2 (VMAT2) have been published as well.

Notes

References

References

1. (October 2003). "Monoamine transporters and psychostimulant drugs". European Journal of Pharmacology.
2. (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry.
3. (July 2008). "Dopamine Transporters: Chemistry, Biology and Pharmacology". Wiley.
4. (June 2013). "Amphetamine, past and present--a pharmacological and clinical perspective". Journal of Psychopharmacology.
5. (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence.
6. (January 2007). "Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions". The AAPS Journal.
7. (2004). "Neurological Aspects of Substance Abuse". Butterworth-Heinemann.
8. (1976). "Competitive problems in the drug industry: hearings before Subcommittee on Monopoly and Anticompetitive Activities of the Select Committee on Small Business, United States Senate, Ninetieth Congress, first session". U.S. Government Printing Office.
9. (1 September 1997). "Ecstasy (MDMA), amphetamine, and LSD: comparative mood profiles in recreational polydrug users". Human Psychopharmacology: Clinical and Experimental.
10. (July 1999). "Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action". Neuropharmacology.
11. (May 2013). "The drug effects questionnaire: psychometric support across three drug types". Psychopharmacology.
12. (March 2006). "Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans". Drug and Alcohol Dependence.
13. (September 2001). "Pharmacodynamics and pharmacokinetics of single nasal (5 mg and 10 mg) and oral (50 mg) doses of ephedrine in healthy subjects". European Journal of Clinical Pharmacology.
14. (October 2001). "Ephedra and its application to sport performance: another concern for the athletic trainer?". Journal of Athletic Training.
15. (1 January 2006). "Central fatigue: the serotonin hypothesis and beyond". Sports Medicine.
16. (March 2010). "Alterations in central fatigue by pharmacological manipulations of neurotransmitters in normal and high ambient temperature". Sports Medicine.
17. (October 2006). "Interaction of amphetamines and related compounds at the vesicular monoamine transporter". J Pharmacol Exp Ther.
18. (May 2021). "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol.
19. (May 2015). "The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter". Eur J Pharmacol.
20. (September 1999). "Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines". Eur J Pharmacol.
21. (July 2011). "Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry". Med Res Rev.
22. Simmler, Linda D.. (2018). "Synthetic Cathinones". Springer International Publishing.
23. (March 2019). "2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors". Psychopharmacology (Berl).
24. (January 2015). "Amphetamines, new psychoactive drugs and the monoamine transporter cycle". Trends Pharmacol Sci.
25. (February 2010). "Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse". Ann N Y Acad Sci.
26. (April 2005). "Mechanisms of neurotransmitter release by amphetamines: a review". Prog Neurobiol.
27. (2020). "Substance Use Disorders". Handb Exp Pharmacol.
28. (2024). "Advances in Pharmacology". Elsevier.
29. (May 2015). "Amphetamine action at the cocaine- and antidepressant-sensitive serotonin transporter is modulated by αCaMKII". J Neurosci.
30. (October 2016). "Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters". Pharmacol Rev.
31. (August 2016). "Striatal dopamine neurotransmission: regulation of release and uptake". Basal Ganglia.
32. (August 2023). "Amphetamine-induced reverse transport of dopamine does not require cytosolic Ca2". J Biol Chem.
33. (March 2012). "Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1)". J Med Chem.
34. (January 2011). "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity". Journal of Neurochemistry.
35. (February 2016). ""TAARgeting Addiction"--The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference". Drug Alcohol Depend.
36. (August 2015). "Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction". Eur J Pharmacol.
37. Miner, Nicholas. (2019). "The Modulatory Role of TAAR1 in Neurotoxicity of Substituted Amphetamines". unav.
38. (October 2019). "The Role of Biogenic Amine Transporters in Trace Amine-Associated Receptor 1 Regulation of Methamphetamine-Induced Neurotoxicity". J Pharmacol Exp Ther.
39. (June 2014). "Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors". Neuropharmacology.
40. (December 2011). "Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class". Bioorganic & Medicinal Chemistry.
41. (March 2021). "Psychoactive Drugs-From Chemical Structure to Oxidative Stress Related to Dopaminergic Neurotransmission. A Review". Antioxidants.
42. (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther.
43. (August 2021). "Pharmacology of Drugs Used as Stimulants". J Clin Pharmacol.
44. (May 2023). "A narrative review of the neuropharmacology of synthetic cathinones-Popular alternatives to classical drugs of abuse". Hum Psychopharmacol.
45. (December 2007). "Trace amine-associated receptor 1-Family archetype or iconoclast?". Pharmacol Ther.
46. (April 2007). "Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine". J Pharmacol Exp Ther.
47. (February 2016). ""TAARgeting Addiction"--The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference". Drug Alcohol Depend.
48. (July 2018). "Trace Amines and Their Receptors". Pharmacol Rev.
49. (October 2018). "Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine". ACS Chem Neurosci.
50. (March 2020). "TAAR1 and Psychostimulant Addiction". Cellular and Molecular Neurobiology.
51. (August 2023). "The Alkylamine Stimulant 1,3-Dimethylamylamine Exhibits Substrate-Like Regulation of Dopamine Transporter Function and Localization". J Pharmacol Exp Ther.
52. (March 2020). "TAAR Agonists". Cell Mol Neurobiol.
53. Reese, Edmund Arthur. (2008). "Trace amine-associated receptor 1: a novel target of methamphetamine".
54. (December 2021). "Potential of Ligands for Trace Amine-Associated Receptor 1 (TAAR1) in the Management of Substance Use Disorders". CNS Drugs.
55. (January 2023). "Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders". Trends Neurosci.
56. (2014). "Taste and Smell". Springer International Publishing.
57. (January 2013). "Pharmacological characterization of designer cathinones in vitro". Br J Pharmacol.
58. (November 2011). "Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA)". J Neurosci.
59. (January 2013). "Amphetamine paradoxically augments exocytotic dopamine release and phasic dopamine signals". J Neurosci.
60. (2013). "Amphetamine elicits opposing actions on readily releasable and reserve pools for dopamine". PLOS ONE.
61. (June 2018). "The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction". Pharmacol Ther.
62. (December 2017). "The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission". Nat Commun.
63. Lam, Vincent. (2017). "Identification and in vivo Characterization of a Potential TAAR1 Antagonist".
64. (July 2015). "Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders". ACS Chem Neurosci.
65. (December 2005). "Targeted screening for biogenic amine transporters: potential applications for natural products". Life Sci.
66. (2007). "The SH rat model of ADHD has profoundly different catecholaminergic responses to amphetamine's enantiomers compared with Sprague-Dawleys". Society for Neuroscience.
67. (June 2013). "Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence". BMC Res Notes.
68. (December 2014). "Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaine". Neuropharmacology.
69. (July 2013). "Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates". The Journal of Pharmacology and Experimental Therapeutics.
70. (2011). "The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors". PLOS ONE.
71. (2012). "Behavioral Neuroscience of Attention Deficit Hyperactivity Disorder and Its Treatment".
72. (June 2022). "Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology". J Psychopharmacol.
73. (1990). "In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis". Synapse.
74. (February 2021). "Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder". Current Opinion in Pharmacology.
75. (May 2004). "Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology & Biological Psychiatry.
76. (August 2003). "Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives". Neurochemical Research.
77. (1996). "Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain". Life Sciences.
78. (August 2022). "Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum". International Journal of Molecular Sciences.
79. (August 2023). "Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline". International Journal of Molecular Sciences.
80. (February 2025). "Regulation by Trace Amine-Associated Receptor 1 (TAAR1) of Dopaminergic-GABAergic Interaction in the Striatum: Effects of the Enhancer Drug (-)BPAP". Neurochem Res.
81. (May 1998). "Characterization of beta-phenylethylamine-induced monoamine release in rat nucleus accumbens: a microdialysis study". European Journal of Pharmacology.
82. (October 2018). "3,4-Methylenedioxymethamphetamine, mephedrone, and β-phenylethylamine release dopamine from the cytoplasm by means of transporters and keep the concentration high and constant by blocking reuptake". European Journal of Pharmacology.
83. (1991). "Pihkal: A Chemical Love Story". Transform Press.
84. (1997). "Tihkal: The Continuation". Transform Press.
85. (2011). "[[The Shulgin Index: Psychedelic Phenethylamines and Related Compounds]]". Transform Press.
86. (April 2021). "Amphetamines signal through intracellular TAAR1 receptors coupled to Gα13 and GαS in discrete subcellular domains". Mol Psychiatry.
87. (April 2009). "Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons". Mol Neurobiol.
88. (January 2019). "Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters". Neurochem Int.
89. (December 2014). "Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders". Pharmacol Ther.
90. (2017). "Neuropharmacology of New Psychoactive Substances (NPS)".
91. Kostrzewa, Richard M.. (2022). "Handbook of Neurotoxicity". Springer International Publishing.
92. (August 2017). "Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms". Prog Neurobiol.
93. (2021). "Is Attention-Deficit/Hyperactivity Disorder a Risk Syndrome for Parkinson's Disease?". Harv Rev Psychiatry.
94. (2015). "Psychostimulants and movement disorders". Front Neurol.
95. (July 2007). "Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD". J Atten Disord.
96. (February 2009). "Potential adverse effects of amphetamine treatment on brain and behavior: a review". Mol Psychiatry.
97. (October 2005). "Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates". J Pharmacol Exp Ther.
98. (2016). "Clinical neuroscience of amphetamine-type stimulants: From basic science to treatment development". Prog Brain Res.
99. (June 2013). "Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?". Atten Defic Hyperact Disord.
100. (2017). "Synthetic Aminoindanes: A Summary of Existing Knowledge". Front Psychiatry.
101. (November 1989). "Studies of dioxole ring substituted 3,4-methylenedioxyamphetamine (MDA) analogues". Pharmacol Biochem Behav.
102. (1994). "Amphetamine and Its Analogs: Psychopharmacology, Toxicology, and Abuse". Academic Press.
103. (March 1998). "Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA)". J Med Chem.
104. (December 1984). "Structure-activity studies on amphetamine analogs using drug discrimination methodology". Pharmacol Biochem Behav.
105. (November 1993). "Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine". J Med Chem.
106. (2013). "Phenethylamine: von der Struktur zur Funktion". Nachtschatten-Verlag.
107. (March 1991). "3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine". Pharmacol Biochem Behav.
108. (December 1994). "Behavioral and developmental effects of two 3,4-methylenedioxymethamphetamine (MDMA) derivatives". Drug Alcohol Depend.
109. (2013). "Phenethylamine: von der Struktur zur Funktion". Nachtschatten-Verlag.
110. (June 2021). "α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenones and high and low affinity monoamine transporters". Neuropharmacology.
111. (January 2017). "Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release". J Pharmacol Exp Ther.
112. "2-Aminoindane compounds for mental disorders or enhancement.".
113. (1993). "Novel serotonergic agents". Drug des Discov.
114. (May 1982). "A new, potent, conformationally restricted analogue of amphetamine: 2-amino-1,2-dihydronaphthalene". J Med Chem.
115. (March 1991). "Structural variation and (+)-amphetamine-like discriminative stimulus properties". Pharmacol Biochem Behav.
116. "Indolizine compounds for the treatment of mental disorders or inflammation".
117. "Indolizine compounds for the treatment of mental disorders or mental enhancement".
118. (2016). "Novel psychoactive benzofurans strongly increase extracellular serotonin level in mouse corpus striatum". J Toxicol Sci.
119. (September 2019). "Pharmacological profiles of compounds in preworkout supplements ("boosters")". Eur J Pharmacol.
120. (June 2008). "Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)". Br J Pharmacol.
121. (August 1990). "Effect of tuamine, heptaminol and two analogues on uptake and release of catecholamines in cultured chromaffin cells". Biochem Pharmacol.
122. (January 2019). "Methylhexaneamine causes tachycardia and pressor responses indirectly by releasing noradrenaline in the rat". Eur J Pharmacol.
123. (February 2018). "Octodrine: New Questions and Challenges in Sport Supplements". Brain Sci.
124. (2012). "Scientific Opinion on the Regulatory Status of 1,3-Dimethylamylamine (DMAA)". European Journal of Food Research & Review.
125. (September 2011). "Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET". Proc Natl Acad Sci U S A.
126. (2016). "History full circle: 'Novel' sympathomimetics in supplements". Drug Test Anal.
127. (2016). "Neurotransmitter Transporters". Springer New York.
128. (1999). "Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc".
129. (1999). "Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc".
130. (September 2012). "Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters". ACS Chem Neurosci.
131. (March 2022). "Aminopropylbenzothiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice". Neuropsychopharmacology.
132. (2011). "Trifluoromethyl ring-substituted methcathinone analogs: activity at monoamine uptake transporters". The FASEB Journal.
133. (March 2014). "Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function". Psychopharmacology (Berl).
134. (June 2014). "Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics". ACS Med Chem Lett.
135. (9 March 2023). "Norfenfluramine to treat dravet syndrome".
136. (2014). "Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse".
137. (2015). "Chemical modifications to alter monoamine releasing activity of phenmetrazine analogs as potential treatments of stimulant addiction". Drug and Alcohol Dependence.
138. (October 2013). "Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys". Int J Neuropsychopharmacol.
139. (May 2005). "Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs". The Journal of Pharmacology and Experimental Therapeutics.
140. (September 2018). "Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers". Drug Test Anal.
141. (April 2009). "Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine". J Pharmacol Exp Ther.
142. (May 2015). "Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues". Br J Pharmacol.
143. (May 2018). "Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family". Neuropharmacology.
144. (October 2018). "DARK Classics in Chemical Neuroscience: Aminorex Analogues". ACS Chem Neurosci.
145. (2014). "Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni')". Drug Testing and Analysis.
146. (September 2017). "N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability". Neuropsychopharmacology.
147. (December 1992). "p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent". Eur J Pharmacol.
148. (December 2012). "4-Methylthioamphetamine increases dopamine in the rat striatum and has rewarding effects in vivo". Basic Clin Pharmacol Toxicol.
149. (April 2014). "Monoamine transporter and receptor interaction profiles of a new series of designer cathinones". Neuropharmacology.
150. (April 2012). "Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters". The Journal of Pharmacology and Experimental Therapeutics.
151. (2017). "Neuropharmacology of New Psychoactive Substances (NPS)".
152. (2018). "New Psychoactive Substances". Handb Exp Pharmacol.
153. (January 2013). "Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs". Eur J Pharmacol.
154. (July 2015). "Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3',4'-methylenedioxy-4-methylaminorex (MDMAR)". Drug Testing and Analysis.
155. (December 2020). "The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats". Psychopharmacology (Berl).
156. (June 2014). "Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys". Experimental and Clinical Psychopharmacology.
157. (February 2016). "The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue". Neuropharmacology.
158. (8 December 2022). "Advantageous benzofuran compositions for mental disorders or enhancement".
159. (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology.
160. (September 2024). "Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine". J Pharmacol Exp Ther.
161. (September 2024). "A "Furious" Effort to Develop Novel 3,4-Methylenedioxymethamphetamine-Like Therapeutics". J Pharmacol Exp Ther.
162. (June 2007). "The Biogenic Amine Transporter Properties of Selected Shulgin Tryptamines (Abstract 50)". College on Problems of Drug Dependence.
163. (June 2020). "Investigation of the Optical Isomers of Methcathinone, and Two Achiral Analogs, at Monoamine Transporters and in Intracranial Self-Stimulation Studies in Rats". ACS Chem Neurosci.
164. Nguyen, Vy. (2019). "Analyzing Interactions Between Methcathinone Analogs and the Human Monoamine Transporters". VCU Theses and Dissertations.
165. Yadav, Barkha J. (16 July 2019). "Understanding Structure–Activity Relationship of Synthetic Cathinones (Bath Salts) Utilizing Methylphenidate".
166. (December 2000). "Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters". Bioorganic & Medicinal Chemistry.
167. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse.
168. (March 2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology.
169. Liu, Yi. (28 March 2018). "Structural Determinants for Inhibitor Recognition by the Dopamine Transporter".
170. (2005). "Structure–activity relationship studies of DAT, SERT, and NET releasers".
171. (March 2005). "N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy')". Neuropsychopharmacology.
172. (October 2004). "Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain". Ann N Y Acad Sci.
173. (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology.
174. "Specialized combinations for mental disorders or mental enhancement".
175. "Advantageous tryptamine compositions for mental disorders or enhancement".
176. (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P1 - P270: P254. Gm-2505 is a Novel 5-Ht2a Receptor Agonist and 5-Ht Releaser That Induces Rapid, Robust, and Durable Antidepressant Effects at Doses Associated With Decreased Power in Low Frequency EEG Bands in Rats". Neuropsychopharmacology.
177. (2022). "Methods of treating mood disorders".
178. Davies, Rachel A. (10 July 2019). "Structure-Activity Relationship Studies of Synthetic Cathinones and Related Agents".
179. (June 2017). "Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release". ACS Chem Neurosci.
180. (March 2019). "The synthetic cathinones, butylone and pentylone, are stimulants that act as dopamine transporter blockers but 5-HT transporter substrates". Psychopharmacology (Berl).
181. (June 2013). "Substituted methcathinones differ in transporter and receptor interactions". Biochem Pharmacol.
182. (February 2016). "Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats". Eur Neuropsychopharmacol.
183. (June 2019). "The Supplement Adulterant β-Methylphenethylamine Increases Blood Pressure by Acting at Peripheral Norepinephrine Transporters". J Pharmacol Exp Ther.
184. (December 2018). "Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors". Biochem Pharmacol.
185. (September 2015). "Ethylenedioxy homologs of N-methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) and its corresponding cathinone analog methylenedioxymethcathinone: Interactions with transporters for serotonin, dopamine, and norepinephrine". Bioorg Med Chem.
186. (March 2019). "Analytical quantification, intoxication case series, and pharmacological mechanism of action for N-ethylnorpentylone (N-ethylpentylone or ephylone)". Drug Test Anal.
187. (March 2024). "Structure-activity relationships for locomotor stimulant effects and monoamine transporter interactions of substituted amphetamines and cathinones". Neuropharmacology.
188. Nicole, Lauren. (2022). "In vivo Structure-Activity Relationships of Substituted Amphetamines and Substituted Cathinones".
189. (April 2021). "Eutylone and Its Structural Isomers Interact with Monoamine Transporters and Induce Locomotor Stimulation". ACS Chem Neurosci.
190. (June 2003). "(+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters". The Journal of Pharmacology and Experimental Therapeutics.
191. (June 2003). "3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro". Molecular Pharmacology.
192. (July 2002). "Therapeutic and adverse actions of serotonin transporter substrates". Pharmacology & Therapeutics.
193. (June 2006). "Interaction of MDMA and its Metabolites at Monoamine Transporters in Rat Brain (Abstract 60)".
194. (June 2013). "Probing the Selectivity of Monoamine Transporter Substrates by Means of Molecular Modeling". Mol Inform.
195. (January 2012). "Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain". Eur J Pharmacol.
196. (April 2002). "Serotonin releasing agents. Neurochemical, therapeutic and adverse effects". Pharmacology, Biochemistry, and Behavior.
197. (January 2016). "Binding Mode Selection Determines the Action of Ecstasy Homologs at Monoamine Transporters". Mol Pharmacol.
198. (April 2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology.
199. Sakloth, Farhana. (11 December 2015). "Psychoactive synthetic cathinones (or 'bath salts'): Investigation of mechanisms of action".
200. (February 2015). "Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats". Br J Pharmacol.
201. (May 2011). "Characterization of pharmacological and wake-promoting properties of the dopaminergic stimulant sydnocarb in rats". J Pharmacol Exp Ther.
202. Shalabi, Abdelrahman R.. (14 December 2017). "Structure-Activity Relationship Studies of Bupropion and Related 3-Substituted Methcathinone Analogues at Monoamine Transporters".
203. (January 2019). "Systematic Structure-Activity Studies on Selected 2-, 3-, and 4-Monosubstituted Synthetic Methcathinone Analogs as Monoamine Transporter Releasing Agents". ACS Chem Neurosci.
204. (November 2021). "Comparative Neuropharmacology and Pharmacokinetics of Methamphetamine and Its Thiophene Analog Methiopropamine in Rodents". Int J Mol Sci.
205. (January 2013). "Neurochemical profiles of some novel psychoactive substances". Eur J Pharmacol.
206. (February 2017). "Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats". Neuropsychopharmacology.
207. (May 2018). "Pharmacological profile of methylphenidate-based designer drugs". Neuropharmacology.
208. (March 2017). "Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone". Drug Test Anal.
209. (June 2005). "Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration". The Journal of Pharmacology and Experimental Therapeutics.
210. (October 2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates". The Journal of Pharmacology and Experimental Therapeutics.
211. (September 2016). "Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters". Br J Pharmacol.
212. (December 2017). "Cocaine-like discriminative stimulus effects of "norepinephrine-preferring" monoamine releasers: time course and interaction studies in rhesus monkeys". Psychopharmacology.
213. Vekariya, Rakesh. (2012). "Towards Understanding the Mechanism of Action of Abused Cathinones". VCU Theses and Dissertations.
214. (April 2017). "The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse". J Med Chem.
215. (5 August 2011). "Drug Discrimination". Wiley.
216. (June 2002). "Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain". European Journal of Pharmacology.
217. Forsyth, Andrea N. (22 May 2012). "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines".
218. (20 May 2011). "Phenylmorpholines and analogues thereof".
219. (11 May 2017). "Vinylogous phenethylamines as neurotransmitter releasers".
220. (2016). "The biogenic amine transporter activity of vinylogous amphetamine analogs". MedChemComm.
221. (January 2021). "Amphetamine-like Neurochemical and Cardiovascular Effects of α-Ethylphenethylamine Analogs Found in Dietary Supplements". J Pharmacol Exp Ther.
222. (April 2024). "Bioisosteric analogs of MDMA with improved pharmacological profile".
223. (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology.
224. (October 2014). "Alpha-ethyltryptamines as dual dopamine-serotonin releasers". Bioorganic & Medicinal Chemistry Letters.
225. (June 2002). "Appetite suppressants as agonist substitution therapies for stimulant dependence". Ann N Y Acad Sci.
226. (July 2018). "Effects of N-Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related Behavior". ACS Chem Neurosci.
227. (September 2000). "Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity". Ann N Y Acad Sci.
228. (June 2023). "Neurochemical and Cardiovascular Effects of 4-Chloro Ring-Substituted Synthetic Cathinones in Rats". J Pharmacol Exp Ther.